FDA OKs Mesenchymal Stromal Cell Therapy for GVHD ...Middle East

Medscape - News
Remestemcel-L (Ryoncil) is an allogeneic bone marrow‒derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-host disease in pediatric patients as young as 2 months. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA OKs Mesenchymal Stromal Cell Therapy for GVHD )

Also on site :